Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Giampiero Giovacchini"'
Autor:
Francesca, Tutino, Elisabetta, Giovannini, Sara, Pastorino, Ornella, Ferrando, Giampiero, Giovacchini, Andrea, Ciarmiello
Publikováno v:
Current Radiopharmaceuticals. 15:259-270
Abstract: Although metabolic tumor volume (MTV) assessed with pretreatment 18F-FDG PET/CT has shown significant prognostic value across many lymphoma types, it is still not used in clinical practice due to technical concerns and the lack of standardi
Autor:
Andrea, Ciarmiello, Elisabetta, Giovannini, Sara, Pastorino, Ornella, Ferrando, Franca, Foppiano, Antonio, Mannironi, Antonio, Tartaglione, Giampiero, Giovacchini
Publikováno v:
Clinical nuclear medicine. 48(1)
The study aimed to develop a deep learning model for predicting amnestic mild cognitive impairment (aMCI) diagnosis using radiomic features and amyloid brain PET.Subjects (n = 328) from the Alzheimer's Disease Neuroimaging Initiative database and the
Autor:
Francesca Tutino, Elisabetta Giovannini, Silvia Chiola, Giampiero Giovacchini, Andrea Ciarmiello
Publikováno v:
Journal of Clinical Medicine. 12:3498
Immune checkpoint inhibitors are currently the standard of care for many advanced solid tumors, and they have been recently approved for the treatment of relapsed/refractory Hodgkin lymphoma and primary mediastinal B cell lymphoma. Assessments of the
Publikováno v:
L'Endocrinologo. 21:344-347
L’encefalopatia di Hashimoto e una rara complicanza cerebrale legata alla malattia di Hashimoto e caratterizzata da una notevole variabilita nella sintomatologia neurologica e psichiatrica. Si caratterizza per elevati livelli di anticorpi anti-pero
Autor:
Andrea Ciarmiello, Sara Pastorino, Elisabetta Giovannini, Valerio Duce, Mattia Riondato, Giampiero Giovacchini, Licia Uccelli
Publikováno v:
Current Radiopharmaceuticals
Background::The rising incidence rate of prostate cancer (PCa) has promoted the development of new diagnostic and therapeutic radiopharmaceuticals during the last decades. Promising improvements have been achieved in clinical practice using prostate
Publikováno v:
Nuclear Oncology ISBN: 9783319260679
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::101fefc81877bfebd07a8354ed0e9460
https://doi.org/10.1007/978-3-319-26067-9_21-2
https://doi.org/10.1007/978-3-319-26067-9_21-2
Autor:
Giampiero Giovacchini, Sara Pastorino, Mattia Riondato, Elisabetta Giovannini, Andrea Ciarmiello
Publikováno v:
Nuclear Oncology ISBN: 9783319260679
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::726918734f65bdc2fd5a483e3a4bbdc0
https://doi.org/10.1007/978-3-319-26067-9_9-2
https://doi.org/10.1007/978-3-319-26067-9_9-2
Autor:
Andrea Ciarmiello, Enrico Conti, Mattia Riondato, Valerio Duce, Giampiero Giovacchini, Rossella Leoncini, Patrizia Lazzeri, Maria Picchio, Elisa Borsò, Elisabetta Giovannini
Publikováno v:
Nuclear Medicine Communications. 40:258-263
Purpose Several factors have been identified that predict positive fluorine-18-fluoromethylcholine (18F-FCH) PET/CT result in patients with prostate cancer undergoing PET/CT for biochemical failure. Among these factors, prostate-specific antigen (PSA
Autor:
Elisabetta Giovannini, Andrea Ciarmiello, Luigi Mansi, Valerio Duce, Elisa Borsò, Giampiero Giovacchini, Rossella Leoncini, Patrizia Lazzeri, Mattia Riondato
Publikováno v:
Journal of Cellular Physiology. 234:14865-14872
Neuropathological and clinical evidence indicates that the clinical expression of Alzheimer's disease (AD) occurs as neuropathology exceeds the brain reserve capacity. The brain or cognitive reserve (BCR) hypothesis states that high premorbid intelli
Autor:
Luigi Gianolli, Elisabetta Giovannini, Maria Picchio, Elena Incerti, Mattia Riondato, Alberto Briganti, Andrea Ciarmiello, Ana Maria Samanes Gajate, Giampiero Giovacchini, Priscilla Guglielmo, Paola Mapelli
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 46:921-929
Purpose: The main drawback of 11C-choline PET/CT for restaging prostate cancer (PCa) patients with biochemical failure is the relatively low positive detection rate for prostate specific antigen (PSA) < 1 ng/ml. This study assessed whether 11C-cholin